VENUSREM — Venus Remedies Share News
0.000.00%
Last trade - 00:00- IN₹16.56bn
- IN₹15.76bn
- IN₹7.70bn
Brief: Venus Remedies Secured Five Marketing Authorisations Across Kazakhstan, Peru, Kuwait And Argentina
India's Venus Remedies rises after quarterly profit more than doubles
Brief: Venus Remedies June-Quarter Consol Net Profit 229.7 Million Rupees
India raises price cap on cancer drugs to tackle shortage
Indian cancer patients battle shortage of key drugs as platinum costs surge
India's Venus Remedies gains after renewal of in-house R&D recognition
Brief: Venus Remedies Receives Saudi FDA Approval For Plerixafor
India's Venus Remedies gains after Q3 profit jump
Brief: Venus Remedies Ltd Received Marketing Authorisation In Indonesia For Its Antibiotic Combination Ceftazidime + Avibactam
Brief: Venus Remedies Receives Final 110 Mln Rupees Payment From Cipla
India's Venus Remedies surges as quarterly profit doubles
India's Venus Remedies jumps on FDA approval for anti-mircrobial resistance therapy
Brief: Venus Remedies Says US FDA Grants QIDP Designation To Venus Remedies' VRP-034
RCS - Infex Therapeutics - Infex signs MET-X agreement with Venus Remedies
India's Venus Remedies gains on exclusive India rights for UK co's drug
Brief: Venus Remedies Secures Exclusive In-Licensing Rights From Infex Therapeutics
India's Venus Remedies surges on renewing EU certificate for Portugal plant
Brief: Venus Remedies Renews EU GMP Certification
India's Venus Remedies rises on Moldovan govt certification